JP2010509315A5 - - Google Patents

Download PDF

Info

Publication number
JP2010509315A5
JP2010509315A5 JP2009535878A JP2009535878A JP2010509315A5 JP 2010509315 A5 JP2010509315 A5 JP 2010509315A5 JP 2009535878 A JP2009535878 A JP 2009535878A JP 2009535878 A JP2009535878 A JP 2009535878A JP 2010509315 A5 JP2010509315 A5 JP 2010509315A5
Authority
JP
Japan
Prior art keywords
substituted
targeting agent
antibody
compound according
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009535878A
Other languages
English (en)
Japanese (ja)
Other versions
JP4897050B2 (ja
JP2010509315A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IE2007/000110 external-priority patent/WO2008056346A2/en
Publication of JP2010509315A publication Critical patent/JP2010509315A/ja
Publication of JP2010509315A5 publication Critical patent/JP2010509315A5/ja
Application granted granted Critical
Publication of JP4897050B2 publication Critical patent/JP4897050B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009535878A 2006-11-10 2007-11-12 抗血管形成化合物 Expired - Fee Related JP4897050B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US86536006P 2006-11-10 2006-11-10
US60/865,360 2006-11-10
US93983007P 2007-05-23 2007-05-23
US60/939,830 2007-05-23
US94532907P 2007-06-20 2007-06-20
US60/945,329 2007-06-20
PCT/IE2007/000110 WO2008056346A2 (en) 2006-11-10 2007-11-12 Anti-angiogenic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011283619A Division JP2012121886A (ja) 2006-11-10 2011-12-26 抗血管形成化合物

Publications (3)

Publication Number Publication Date
JP2010509315A JP2010509315A (ja) 2010-03-25
JP2010509315A5 true JP2010509315A5 (OSRAM) 2010-12-16
JP4897050B2 JP4897050B2 (ja) 2012-03-14

Family

ID=39364902

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009535878A Expired - Fee Related JP4897050B2 (ja) 2006-11-10 2007-11-12 抗血管形成化合物
JP2011283619A Ceased JP2012121886A (ja) 2006-11-10 2011-12-26 抗血管形成化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011283619A Ceased JP2012121886A (ja) 2006-11-10 2011-12-26 抗血管形成化合物

Country Status (18)

Country Link
US (3) US8288349B2 (OSRAM)
EP (2) EP2368908A3 (OSRAM)
JP (2) JP4897050B2 (OSRAM)
KR (2) KR20120043028A (OSRAM)
CN (1) CN101611053B (OSRAM)
AT (1) ATE520712T1 (OSRAM)
AU (1) AU2007318912B2 (OSRAM)
BR (1) BRPI0718591A2 (OSRAM)
CA (1) CA2669207A1 (OSRAM)
DK (1) DK2089425T3 (OSRAM)
IL (1) IL198581A (OSRAM)
MX (1) MX2009005045A (OSRAM)
MY (1) MY146985A (OSRAM)
NO (1) NO20092203L (OSRAM)
NZ (1) NZ576751A (OSRAM)
PL (1) PL2089425T3 (OSRAM)
PT (1) PT2089425E (OSRAM)
WO (1) WO2008056346A2 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4897050B2 (ja) * 2006-11-10 2012-03-14 コヴェックス・テクノロジーズ・アイルランド・リミテッド 抗血管形成化合物
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
US8293714B2 (en) * 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
WO2010036930A1 (en) * 2008-09-26 2010-04-01 Javad Parvizi Methods and kits for detecting joint infection
JP5913307B2 (ja) * 2010-07-12 2016-04-27 コヴェックス・テクノロジーズ・アイルランド・リミテッド 多機能性抗体複合体
WO2012059873A2 (en) 2010-11-05 2012-05-10 Covx Technologies Ireland, Ltd. Anti-diabetic compounds
MX358726B (es) 2011-06-29 2018-09-03 Amgen Inc Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales.
EP2793950A2 (en) 2011-12-20 2014-10-29 Pfizer Inc Improved processes for preparing peptide conjugates and linkers
JP6413127B2 (ja) * 2012-01-09 2018-10-31 コヴェックス・テクノロジーズ・アイルランド・リミテッド 変異抗体およびそのコンジュゲーション
MX350202B (es) 2012-03-28 2017-08-30 Amgen Inc Combinaciones de agonistas de receptores de muerte 5 (dr5).
CA2913387C (en) * 2013-06-12 2024-05-21 Pharis Biotec Gmbh Peptides with antagonistic activities against natural cxcr4
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
AU2014337555C1 (en) * 2013-10-15 2021-01-28 Seagen Inc. PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics
US20190004048A1 (en) 2015-06-26 2019-01-03 Amgen Inc. Biomarker of Survival in the Treatment of Renal Cell Carcinoma with a VEGFR Inhibitor and an Ang2 Inhibitor
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
TWI852735B (zh) 2015-12-04 2024-08-11 美商思進公司 四級胺化妥布賴森(tubulysin)化合物之結合物
KR102626498B1 (ko) 2016-03-25 2024-01-19 씨젠 인크. 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US11730822B2 (en) 2017-03-24 2023-08-22 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
ES3066090T3 (en) 2017-04-28 2026-05-11 Ajinomoto Co Inc Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5216132A (en) 1990-01-12 1993-06-01 Protein Design Labs, Inc. Soluble t-cell antigen receptor chimeric antigens
DE69126871T2 (de) 1990-04-06 1998-03-12 Jolla Cancer Res Found Verfahren und verbindung zur behandlung von thrombose
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6080840A (en) 1992-01-17 2000-06-27 Slanetz; Alfred E. Soluble T cell receptors
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5733757A (en) 1995-12-15 1998-03-31 The Scripps Research Institute Aldolase catalytic antibody
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6326176B1 (en) 1997-12-18 2001-12-04 The Scripps Research Institute Aldol condensations by catalytic antibodies
JP2003516121A (ja) 1999-09-27 2003-05-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 不可逆的に結合するエンジニアリング抗体
US6294374B1 (en) 1999-10-08 2001-09-25 The Scripps Research Institute Use of catalytic antibodies for synthesizing epothilone
AU2002319402B2 (en) 2001-06-28 2008-09-11 Domantis Limited Dual-specific ligand and its use
US20030045477A1 (en) 2001-07-26 2003-03-06 Fortuna Haviv Peptides having antiangiogenic activity
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
WO2003059251A2 (en) * 2001-10-22 2003-07-24 The Scripps Research Institute Antibody targeting compounds
US6737524B2 (en) * 2002-03-25 2004-05-18 Paul K. Smith Activated polyethylene glycol compounds
EP1600459A3 (en) 2002-06-28 2005-12-07 Domantis Limited Ligand
JP2006523090A (ja) 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
CA2572765C (en) 2004-07-08 2013-05-21 Amgen Inc. Compound having improved bioefficiency when administered in a multidose regimen
US7442778B2 (en) * 2004-09-24 2008-10-28 Amgen Inc. Modified Fc molecules
JP4897050B2 (ja) * 2006-11-10 2012-03-14 コヴェックス・テクノロジーズ・アイルランド・リミテッド 抗血管形成化合物

Similar Documents

Publication Publication Date Title
WO2008056346B1 (en) Anti-angiogenic compounds
JP7403507B2 (ja) 薬物としてアマトキシンの誘導体を有する抗体薬物コンジュゲート
KR102209395B1 (ko) 새로운 약물-단백질 접합체
JP2010514835A5 (OSRAM)
CN112601522B (zh) 抗体-alk5抑制剂偶联物及其用途
JP2019501141A (ja) 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート
KR20200117992A (ko) 항-cd22 항체-메이탄신 컨쥬게이트, 그것의 조합, 및 사용 방법
RU2012157167A (ru) Полифункциональные антительные конъюгаты
AU2016354009B2 (en) Anti-CD22 antibody-maytansine conjugates and methods of use thereof
US20140079722A1 (en) Extracellular targeted drug conjugates
JP2008515889A5 (OSRAM)
IL294321A (en) Antibody-drug conjugates are attached at a specific site with linkers that include peptides
JP7854462B2 (ja) 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用
JP2026000988A (ja) Ａｌｋ５阻害剤複合体およびその使用
KR20240083174A (ko) 종양 관련 칼슘 신호 전달 인자 2 (tacstd2) 항체-메이탄신 접합체 및 이의 사용 방법
KR20230133316A (ko) 항체-약물 접합체를 위한 이중 절단 에스테르 링커
RU2418003C2 (ru) Антиангиогенные соединения
CN120731092A (zh) 用于靶向肿瘤相关巨噬细胞的组合物和方法
RU2859790C2 (ru) Сложноэфирные линкеры с двойным расщеплением для конъюгатов антитело-лекарственное средство
RU2011127520A (ru) Соединения агонисты рецептора глюкагоноподобного белка-1 (glp-1r)